Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KRAS | P01116 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13139566 | 0.85 | HTR7 (0.53) | HTR7NPC1ARCYP1A2KRAS | |
| SCHEMBL2873839 | 0.83 | KMT2A (0.54) | HTR7NPC1ARCYP1A2L3MBTL1 | |
| SCHEMBL2870320 | 0.83 | KMT2A (0.54) | HTR7NPC1ARCYP1A2L3MBTL1 | |
| SCHEMBL3356235 | 0.82 | HTR7 (0.50) | HTR7NPC1ARCYP1A2KRAS | |
| SCHEMBL1122247 | 0.82 | ALDH1A1 (0.52) | HTR7NPC1MAPTALDH1A1 | |
| SCHEMBL3356863 | 0.82 | HTR7 (0.50) | HTR7NPC1ARCYP1A2L3MBTL1 | |
| SCHEMBL3354019 | 0.82 | HTR7 (0.50) | HTR7NPC1ARCYP1A2KRAS | |
| SCHEMBL3312100 | 0.79 | HTR7 (0.57) | HTR7NPC1ARCYP1A2CDC7 | |
| SCHEMBL3062365 | 0.79 | HTR7 (0.47) | HTR7NPC1ARCYP1A2KRAS | |
| SCHEMBL1122371 | 0.78 | HTR7 (0.58) | HTR7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2141163-A1 | Substituted thiazolidinones, their production and utilisation as medicine | Bayer Schering Pharma AG (DE) | 2010-01-06 | — | — | EP | disclosed |